Infections

All Conditions

Symptoms and General Pathology

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Immune System Diseases

Neoplasms

Rare Diseases

Communicable Diseases

Uterine Cervical Diseases

Acquired Immunodeficiency Syndrome

HIV Infections

Uterine Cervical Neoplasms

Uterine Neoplasms

Genital Neoplasms, Female

Urogenital Neoplasms

Uterine Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Cervical Intraepithelial Neoplasia

All Drugs and Chemicals

Anti-Inflammatory Agents

Antineoplastic Agents

Antirheumatic Agents

Analgesics

Herbal and Botanical

Turmeric extract

Curcumin

Anti-Inflammatory Agents, Non-Steroidal

Analgesics, Non-Narcotic

Enzyme Inhibitors

Turmeric

Participants in this arm will use 2000 mg of intravaginal curcumin once a week for 20 weeks

Participants in this arm will use 2000 mg of intravaginal placebo once a week for 20 weeks

Curcumin (Curcumin C3 Complex prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventative and therapeutic benefits.

Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.

Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes.

Curcumin C3 Complex

Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules once a week (excluding days when they are on their menses) for 20 weeks. Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.

Cervical cytology and HPV testing will be performed at baseline and 6 months after the baseline visit. If cervical cytology or HPV testing is abnormal at 6 months, a colposcopy with biopsies will be performed. All samples will be used to analyze for the study outcomes.

Placebo

Lisa Flowers, MD

The purpose of this study is to see if curcumin can suppress HPV infection in women with low-grade squamous intraepithelial lesions (LSIL) disease or treated high-grade squamous intraepithelial lesions (HSIL) disease. This study plans to explore the effect of curcumin as a potential medical treatment in HIV-uninfected and infected women with mild precancerous lesions of the cervix or recently treated high-grade precancerous lesions at risk for persistent HPV infection. About 200 women with low-grade precancerous lesions of the cervix or recently treated high-grade precancerous lesions will be enrolled to either insert 2000 mg of curcumin capsules in their vagina once a week or placebo after undergoing colposcopy or loop electrosurgical excision procedure (LEEP). They will have a repeat visit in 6 months where they will undergo a Pap smear and HPV test to determine if there are higher rates of HPV clearance after curcumin administration. If HPV is present or the Pap smear is abnormal, patients will then undergo colposcopic examination to evaluate cervical histology.

Cervical cancer is the third most common cancer worldwide. The causative agent responsible for cervical cancer is the persistent infection with oncogenic Human Papillomavirus (HPV). Rates of cervical cancer and HPV infection are increased particularly in HIV-infected women due to immunosuppression with cervical cancer categorized as an AIDS-defining diagnosis. Despite the promise of HPV vaccine in the prevention of cervical cancer, the widespread availability of this vaccine is limited due to cost and accessibility. Therefore, prevention strategies to reduce the risk of cervical cancer after HPV exposure entail treatment at the premalignant state, including low-grade squamous intraepithelial lesions (LSIL) and high-grade squamous intraepithelial lesions (HSIL), along with the eradication of HPV infection. There is a desperate need for an inexpensive, non-invasive alternative method to treat these premalignant cervical lesions and potentially suppress HPV infection.

Curcumin, an extract from turmeric, a popular culinary spice, has been used in traditional Indian medicine for its anti-inflammatory and anti-infectious properties. Recent studies have shown the potential effect of curcumin to reduce tumors and precancerous lesions in animal and human cancer cells. It is postulated that curcumin achieves its effect on cancer cells by modulating different cellular pathways as well as altering HPV effect on tissue cells.

The purpose of this study is to see if curcumin can suppress HPV infection in women with LSIL disease or treated HSIL disease. The researchers plan to explore the effect of curcumin as a potential medical treatment in HIV-uninfected and infected women with mild precancerous lesions of the cervix or recently treated high-grade precancerous lesions at risk for persistent HPV infection. About 200 women with low-grade precancerous lesions of the cervix or recently treated high-grade precancerous lesions will be enrolled to either insert 2000 mg of curcumin capsules in their vagina once a week or placebo after undergoing colposcopy or LEEP. They will have a repeat visit in 6 months where they will undergo a Pap smear and HPV test to determine if there are higher rates of HPV clearance after curcumin administration. If HPV is present or the Pap smear is abnormal, patients will then undergo colposcopic examination to evaluate cervical histology.

Topical Curcumin for HPV Related Cervical Disease

An Investigation in the Use of Curcumin Topical Herbal Agent for the Treatment of Cervical Intraepithelial Neoplasia

Individual participant data that underlie the published results will be made available for sharing after deidentification.

The treatment will be considered tolerable if 25% or fewer of participants discontinue the study early.

HPV clearance, assessed as the number of participants with undetectable high-risk HPV mRNA levels in the standard monolayer Pap test (ThinPrep), at 6 months will be compared between the curcumin and placebo study arms.

Disease recurrence will be assessed either cytologic or histologic abnormality at 6 months. Rates of disease recurrence will be compared between study arms in HIV-uninfected and infected women.

Lisa Flowers

Professor

Carcinoma

Carcinoma in Situ

Uterine Cervical Dysplasia

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Precancerous Conditions

Anti-Infective Agents

Vitamins

Acetic Acid

Retinol acetate

HRME will capture images from all areas considered abnormal by VIA (visual inspection with acetic acid) and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed

HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed

HRME examination

Jose H Fregnani, PhD

Rui M Reis, PhD

STUDY PURPOSES: This study aims to evaluate a high resolution microendoscope (HRME): 1) To assess the sensitivity and specificity of the HRME device in the detection of cervical intraepithelial neoplasia grade 2 (CIN2) or histologically more severe lesion (NIC2+) and cervical intraepithelial neoplasia grade 3 (CIN3) or histologically more severe lesion (NIC3+) in a comprehensive case-by-case basis; 2) Compare the accuracy of the HRME device with acetic acid visualization (VIA) and colposcopy. METHODOLOGY: 1,780 women with abnormal Pap Smears (ASCUS+) or positive high-risk human papillomavirus (HPV) test in the cervix performed in the Barretos Cancer Hospital (HCB, Barretos, Brazil) screening program will be recruited, either at Mobile Prevention Units or Fixed Units, who have been referred for diagnostic investigation with colposcopy. The invitation for women to participate in the study will be made immediately before the medical consultation for colposcopy, in the Prevention Department of Barretos Cancer Hospital. Women who decide to participate in this study will sign an Informed Consent Form after invitation and relevant explanations, which will be provided by the researcher in charge or by a representative with previous training appointed by him for the application of the Form in question. During the colposcopy examination, the HRME device will be used to check the presence of precursor lesions in the cervix. HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. Any abnormal areas detected by VIA and/or colposcopy will undergo a biopsy. If no abnormal area is observed, a cervical microbiopsy will be obtained from an apparently normal area examined using HRME. If during the study a precursor disease or cervical cancer is detected in any woman, an appropriate treatment will be offered by Barretos Cancer Hospital according to an institutional protocol.

STUDY DESIGN:

This is an experimental methodological study with a single-arm, unmasked, unicentric, international diagnostic device.

OUTLINES:

1,780 women with abnormal Pap Smears (ASCUS+) or positive high-risk HPV test in the cervix performed in the Barretos Cancer Hospital (HCB, Barretos, Brazil) screening program will be recruited, either at Mobile Prevention Units or Fixed Units, who have been referred for diagnostic investigation with colposcopy. During the colposcopy examination, the HRME device will be used to check the presence of precursor lesions in the cervix.

PRE-TESTING VERIFICATION:

As this research may include cervical biopsy in women with fertility, for safety reasons, the possibility of pregnancy in this group of women will be verified, since biopsy performed in the cervix of pregnant woman increases the risk of abortion. This verification will be performed by means of clinical history (menstrual delay, signs suggesting pregnancy, contraceptive methods, etc.) and also by means of qualitative research on human chorionic gonadotropin in urine. This test is also known as "rapid pregnancy test" or "pharmacy test", with an extensive list of products sold in Brazil and authorized by "Agencia Nacional de Vigilancia Sanitária" (ANVISA, Brazilian Agency of Health Surveillance). The principle of the test involves a single step immunochromatographic method to detect the hormone. Reaction occurs on a reagent strip, where a small amount of urine is deposited. Test result is provided in approximately 2 minutes. Women who are pregnant (or suspected to be pregnant) will not be included in the study, but will be submitted to diagnostic investigation according to the institutional protocol for pregnant women with changes in the cervix at HCB. These women will receive medical orientation and will be referred to a specialized obstetrical service.

COLLECTION OF CERVICAL CYTOLOGY:

Before the diagnostic examinations are performed, the doctor will collect a new cervical cytology (Papanicolaou), which is part of the routine of the Department of Colposcopy for every woman who has an altered Pap Smear or positive HPV test. These samples will be preserved in an ethanol-based preservative medium (SurePath™ Preservative Fluid, Becton \& Dickinson, USA) and will be sent to the Department of Pathology of HCB where they will undergo an automated processing for the preparation of cytology slides.

DIAGNOSTIC EXAMINATIONS:

VIA will be performed using 3-5% acetic acid, applied on the cervix and to any abnormal lesions observed. Then, iodine solution will be applied, and the colposcopy will be performed. It is necessary to clarify that the application of acetic acid and iodine is routinely performed during a standard colposcopy examination.

Then, Proflavine (0.01%) will be applied to the surface of the cervix. HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed. The person responsible for the colposcopy will take note of your opinion about the lesion and HRME image at each area (normal, benign, low-grade precancerous, high-grade precancerous or cancer). The complete HRME imaging procedure will add 5-10 minutes to the standard colposcopy examination. Observations related to VIA, colposcopy and HRME will be registered by quadrant. Any abnormal areas detected by VIA and/or colposcopy will undergo a biopsy. If no abnormal area is observed, but the woman has an altered cytology test or a positive HPV test, a cervical microbiopsy will be obtained from an apparently normal area captured by HRME imaging of that area. For all cervical biopsies, special tweezers will be used, causing minimal tissue trauma (microbiopsy) and reducing participant discomfort. These tweezers are different from those commonly used in colposcopy tests, which usually perform biopsies on large areas and bring more discomfort to women.

Two experienced HCB pathologists, ignoring all study results, will review histology and classify areas as normal, cervical intraepithelial neoplasia grade 1 (CIN 1), CIN 2, CIN 3, adenocarcinoma in situ (AIS) or cancer according to standardized criteria. Conflicting results will be resolved by means of consensus review among pathologists.

HIGH-RISK HPV SCREENING AND GENOTYPING:

High-risk HPV screening will be performed on aliquots of cervical cytology samples (SurePath™) collected just prior to colposcopy in women who have not been submitted to this test yet. HPV test will be performed on a Cobas X480 ™ device (Roche Molecular Systems, USA), which is available at the technology park of the Molecular Oncology Research Center of Barretos Cancer Hospital - Pio XII Institution. The test protocol will be performed as described by the manufacturer.

COBAS system is an automated amplification device (by means of real time polymerase chain reaction (PCR)) for the detection of 14 high-risk HPV types (16, 18 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68), and can process up to 94 simultaneous samples. Tests which detected high-risk non-16 and non-18 HPV will be submitted to complementary analysis to identify genotype(s) using the linear array technique, since COBAS system does not provide genotyping of these high-risk HPVs. For this purpose, linear array HPV genotyping (CE-IVD) Test for HPV Genotyping kit (Roche Molecular Systems, USA) will be used.

DATA ANALYSIS:

The primary endpoint is the diagnosis rate of CIN2+ and CIN3+. Sensitivity and diagnostic specificity of VIA, colposcopy and HRME based on each lesion and each patient using histological diagnosis as gold standard will be calculated assuming lesions diagnosed as CIN2 + or CIN3 + are positive. Sensitivity and specificity of VIA and colposcopy will also be calculated as a comparison method.

A case-by-case description will be made using descriptive statistics. Categorical variables will be compared by means of the chi-square test or Fisher's exact test, depending on the expected values in the contingency tables. To compare numerical variables, the t-tests or the Mann-Whitney test will be used depending on the adherence to normality (to be verified by the Kolmogorov-Smirnov test).

SAMPLE SIZE CALCULATION:

Sample calculation was based on information from other studies of the same group (including data not yet published). The following premises were taken: HRME sensitivity and specificity for CIN2+ diagnosis (93% and 48%, respectively, per biopsy area) and prevalence of CIN2+ in the colposcopy clinic of HCB (ranging from 20 to 30%). Considering a prevalence of disease of 25% , it is estimated that it will be necessary to include 1,424 women (625 cases for sensitivity calculation and 799 cases for specificity calculation) to reach the expected sensitivity and specificity rates with a maximum margin of error of 4% for a 95% confidence interval. Considering an estimated loss of 10-15% (non-attendance for colposcopy examination and HRME), the corrected sample estimate will range from 1,566 to 1,637 women. Therefore, the study intends to include 1,600 women with abnormal cervical cytology or positive HPV test. Additionally, a group of women with no change in cervical cytology and HPV test will be invited to participate in the research in order to check verification bias. This bias occurs when only the positive cases in the screening are selected to perform complementary diagnostic examinations, overestimating the sensitivity and underestimating the specificity. It is recommended that a percentage of negative cases be verified according to the standard gold examination. Therefore, 10% of the study population will consist of negative cases in both cervical cytology and the HPV test, which corresponds to nearly 180 cases. Thus, the final sample estimate will be of 1,780 women, of whom 1,600 women will have screening (altered cytology or positive HPV test) results reported as positive and 180 will have screening results reported as negative (negative cytology and HPV test).

STUDY SCHEDULE:

The study will last 3 years.

HRME in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil)

Validation of High Resolution Microendoscope in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil)

RedCap Platform will be used to share data.

Sensitivity and Specificity of CIN2+ and CIN3+ detection using HRME

Comparison of sensitivity and specificity of CIN2+ and CIN3+ with colposcopy and VIA

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Topical Curcumin for HPV Related Cervical Disease	NCT04266275	Neoplasm Cervix	Curcumin C3 Com... Placebo	21 Years -	Emory University
HRME in the Screening of Cervical Cancer Precursor Lesions in Brazil (UH3 - Brazil)	NCT03195218	Intraepithelial... Intraepithelial... Cervical Cancer Neoplasm Cervix	HRME examinatio...	18 Years -	Barretos Cancer Hospital

Spots Global Cancer Trial Database for neoplasm cervix